Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Open accessThe DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.
Abstract
Benzodiazepines are some of the most commonly prescribed medications in the world. These sedative-hypnotics can provide rapid relief for symptoms like anxiety and insomnia, but are also linked to a variety of adverse effects (whether used long-term, short-term, or as needed). Many patients take benzodiazepines long-term without ever receiving evidence-based first-line treatments (e.g., psychotherapy, relaxation techniques, sleep hygiene education, serotonergic agents). This review discusses the risks and benefits of, and alternatives to benzodiazepines. We discuss evidence-based indications and contraindications, and the theoretical biopsychosocial bases for effectiveness, ineffectiveness and harm. Potential adverse effects and drug-drug interactions are summarized. Finally, both fast-acting/acute and delayed-action/chronic alternative treatments for anxiety and/or insomnia are discussed. Response to treatment—whether benzodiazepines, other pharmacological agents, or psychotherapy—should be determined based on functional recovery and not merely sedation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Benzodiazepines are commonly prescribed for anxiety and insomnia but are often misused for their sedative effects [64, 65].”
From Prevalence and patterns of substance use in West Africa: A systematic review and meta-analysis (2024) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
Neurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943 · cited 10×
“However, the study [21] acknowledged the difficulty prescribers face when they “inherit” patients who previously received BZDs from other prescribers (many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to balance individual patient factors with the need to provide evidence-ba…”
BackgroundInfluentialSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519 · cited 9×
“However, the study [21] acknowledged the difficulty prescribers face when they “inherit” patients who previously received BZDs from other prescribers (many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to balance individual patient factors with the need to provide evidence-ba…”
BackgroundInfluentialOpioid-induced Hyperalgesia: A Qualitative Systematic Review
Angst, M. S., & Clark, J. D. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00025 · Cited by 1,188
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041 · cited 1×
“High rates of comorbidity suggest that PTSD and SUDs are functionally related, a concept supported by several studies indicating a pathway (likely related to corticotropin-releasing hormone and norepinephrine) whereby PTSD precedes substance use [69].”
BackgroundFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927 · cited 1×
“These “antidepressants” (that are not only effective for depression) typically take four to six weeks before they exert clinical effect, though in the treatment of anxiety symptoms this delay can be even longer [30].”
BackgroundComparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia
Smith, M. T., Perlis, M. L., Park, A., Smith, M. S., Pennington, J., Giles, D. E., & Buysse, D. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.5 · Cited by 863 · cited 2×
“…SAD and insomnia, BZDs are frequently overprescribed for other indications for which there is no evidence of efficacy, to individuals who have contraindicated comorbid conditions, for longer periods of time than are recommended, and before other first and second-line treatments are tried [52–57].”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Research works printed but not linked: 7
- Pary R. Lewis S. Prescribing benzodiazepines in clinical practice Resid. Staff Phys. 2008 54 8 17
- National Institute for Health and Care Excellence (NICE) Generalised Anxiety Disorder and Panic Disorder in Adults: Management 2011 Available online: https://www.nice.org.uk/guidance/cg113 (accessed on 25 October 2017) 31961629
- Stahl S.M. Essential Psychopharmacology 4th ed. Cambridge New York, NY, USA 2013
- Powers M. Becker E. Gorman J. Kissen D. Smits J. Anxiety and Depression Association of America Clinical Practice Review for GAD 2015 Available online: https:/adaa.org (accessed on 20 October 2017)
- Foa E.B. Keane T.M. Friedman M.J. Cohen J.A. Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies 2nd ed. Guilford Press New York, NY, USA 2009 566
- Ader R. Psychoneuroimmunology Elsevier Academic Press Burlington, MA, USA 2006
- Yonkers K.A. Spinelli M. Pharmacological issues during pregnancy Psychiatry 3rd ed. Tasman A. Kay J. Lieberman J.A. John Wiley & Sons Chichester, UK 2008 Volume 1 2423 2424
Cited by
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 194
“GABAAR PAMs including benzodiazepines are used for treating epilepsy and forms of anxiety disorder 192 .”
Sumsuzzman, D. M., Choi, J., Jin, Y., & Hong, Y. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.04.034 · Cited by 123
Detyniecki, K., Van Ess, P. J., Sequeira, D. J., Wheless, J. W., Meng, T., & Pullman, W. E. (2019) · Epilepsia · doi:10.1111/epi.15159 · Cited by 105
Massoudi, B., Holvast, F., Bockting, C. L. H., Burger, H., & Blanker, M. H. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.11.050 · Cited by 101
Long-term use of benzodiazepines in chronic insomnia: a European perspective
Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 121
“Furthermore, BZDs may lower the threshold for suicidal behavior in patients with depression (71).”
BackgroundSaleh, N. M., El-Gaby, M. S. A., El‐Adl, K., & El‐Sattar, N. E. A. A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104350 · Cited by 96
Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
Brunetti, P., Giorgetti, R., Tagliabracci, A., Huestis, M. A., & Busardò, F. P. (2021) · Pharmaceuticals · doi:10.3390/ph14060560 · Cited by 111
“Due to controlled neuronal inhibition and lower CNS depression risk, BZD rapidly replaced older medications such as barbiturates, meprobamate and chloral hydrate, becoming the most prescribed drug class in the world during the 1970s [11,12].”
BackgroundOstuzzi, G., Papola, D., Gastaldon, C., Schoretsanitis, G., Bertolini, F., Amaddeo, F., Cuomo, A., Emsley, R. A., Fagiolini, A. M., Imperadore, G., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01685-9 · Cited by 110
“Although the risk of respiratory suppression with benzodiazepines is notably lower than barbiturates or other neuromuscular blocking agents [21, 50, 52], it may be relevantly high in people with acute respiratory distress and in the elderly [33, 42, 80, 88].”
BackgroundDitmer, M., Gabryelska, A., Turkiewicz, S., Białasiewicz, P., Małecka-Wojciesko, E., & Sochal, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010067 · Cited by 94
Anxiety: An ignored aspect of Parkinson’s disease lacking attention
Khatri, D. K., Choudhary, M., Sood, A., & Singh, S. B. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110776 · Cited by 94
Mallappa, Chahar, M., Choudhary, N., Yadav, K. K., Qasim, M. T., Zairov, R., Patel, A., Yadav, V. K., & Jangir, M. (2024) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-024-03142-3 · Cited by 105
“The therapeutic potential of these compounds is mainly due to their potential to interact with several biological targets involved in the CNS [128].”
Torres-Bondia, F., de Batlle, J., Galván, L., Buti, M., Barbé, F., & Piñol-Ripoll, G. (2020) · BMC Public Health · doi:10.1186/s12889-020-08984-z · Cited by 69
Top Ten Tips Palliative Care Clinicians Should Know About Psychopharmacology
Riordan, P. A., Briscoe, J. G., Uritsky, T. J., Jones, C. A., & Webb, J. A. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0106 · Cited by 63
“23 56 The National Comprehensive Cancer Network (NCCN) recommends benzodiazepines for anticipatory nausea second-line to behavioral interventions and other first-line treatments.”
InfluentialAlabaku, O., Yang, A., Tharmarajah, S., Suda, K. J., Vigod, S. N., & Tadrous, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284389 · Cited by 74
“This is expected because although BZDs have been proven effective in treating numerous conditions such as anxiety, agitation, and insomnia, their side effect profile is problematic [29].”
BackgroundChallenges and opportunities in insomnia disorder
Roach, M., Juday, T. R., Tuly, R., Chou, J. W., Jena, A. B., & Doghramji, P. P. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1773460 · Cited by 68
“Despite the evidence implicating BZDs in some important adverse outcomes, many patients are still treated with BZDs well beyond the clinical guidelines of 2–4weeks [53].”
BackgroundHassan, F., Edo, G. I., Nwosu, L. C., Jalloh, A. A., Onyibe, P. N., Itoje-akpokiniovo, L. O., & Irogbo, P. U. (2021) · Acta Ecologica Sinica · doi:10.1016/j.chnaes.2021.11.003 · Cited by 66
Falk, E., Schlieper, D., van Caster, P., Lutterbeck, M. J., Schwartz, J., Cordes, J., Grau, I., Kienbaum, P., & Neukirchen, M. (2020) · BMC Palliative Care · doi:10.1186/s12904-019-0499-1 · Cited by 57
“Benzodiazepines have a fast onset of action, but also limiting side effects like sedation, confusion, loss of coordination, addiction and paradox effects [56, 57].”
BackgroundSigurdsson, M. I., Helgadóttir, S., Long, T. E., Helgason, D., Waldron, N. H., Pálsson, R., Indridason, Ó. S., Guðmundsdóttir, I. J., Guðbjartsson, T., & Sigurdsson, G. H. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.1652 · Cited by 58
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000316 · Cited by 50
Fear and anxiety managing methods during dental treatments: a systematic review of recent data
Stefano, R. D., Bruno, A., Muscatello, M. R. A., Cedro, C., Cervino, G., & Fiorillo, L. (2020) · Minerva Dental and Oral Science · doi:10.23736/s0026-4970.19.04288-2 · Cited by 59
Wheless, J. W., Meng, T., Ess, P. J. V., Detyniecki, K., Sequeira, D. J., & Pullman, W. E. (2019) · Epilepsia · doi:10.1111/epi.16300 · Cited by 51
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020020 · Cited by 48
“, tolerance and/or withdrawal) in the absence of misuse should lead the prescriber and patient to engage in discussions that weigh the risks and benefits of continuing BZDs, or changing to more effective and/or safer alternatives (see Table 1) [12].”
BackgroundSelf-citationA review on the chemistry and pharmacological properties of benzodiazepine motifs in drug design
Tolu-Bolaji, O. O., Sojinu, S. O., Okedere, A. P., & Ajani, O. O. (2022) · Arab Journal of Basic and Applied Sciences · doi:10.1080/25765299.2022.2117677 · Cited by 51
“They are also applicable in the treatment or cure for nervousness disorders, and general unease syndromes, as additions for treatment of neurotic–driven condition (Griffin, Kaye, Bueno, & Kaye, 2013; Guina & Merrill, 2018).”
BackgroundA Carbon-Dot Sensing Probe for Screening of Date Rape Drugs: Nitro-containing Benzodiazepines
Yen, Y., Lin, Y., Chen, T., Chyueh, S., & Chang, H. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.127441 · Cited by 41
Biskupiak, Z., Ha, V. V., Rohaj, A., & Bulaj, G. W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020403 · Cited by 52
Maideen, N. M. P. (2019) · World Journal of Pharmacology · doi:10.5497/wjp.v8.i2.14 · Cited by 43
Vitexin Possesses Anticonvulsant and Anxiolytic-Like Effects in Murine Animal Models
Oliveira, D. D., da Silva, C. P., Benincasa, B. I., & Beleboni, R. O. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01181 · Cited by 41
“…impairment or severe sedation are constantly claimed as important side effects caused by different pharmacological agents used in the treatment of anxiety and epilepsy and should be avoided in the clinical management of those medical conditions (Canevini et al., 2010; Guina and Merrill, 2018).”
BackgroundLong-Term Use of Insomnia Medications: An Appraisal of the Current Clinical and Scientific Evidence
Zee, P. C., Bertisch, S. M., Morin, C. M., Pelayo, R., Watson, N. F., Winkelman, J. W., & Krystal, A. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041629 · Cited by 41
Scarfone, K. M., Maghsoudi, N., McDonald, K., Stefan, C., Beriault, D. R., Wong, E., Evert, M., Hopkins, S., Leslie, P., Watson, T. M., et al. (2022) · Harm Reduction Journal · doi:10.1186/s12954-021-00585-2 · Cited by 39
“Benzodiazepines elicit sedative and anxiolytic effects that, when combined with other central nervous system depressants, may amplify cardiovascular and respiratory depression and contribute to overdose severity [18].”
BackgroundTRPV1 blockers as potential new treatments for psychiatric disorders
Iglesias, L. P., de Aguiar, D. C., & Moreira, F. A. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000603 · Cited by 36
“Various drugs used in the treatment of psychiatric disorders cause side effects, tolerance and withdrawal symptoms after long-term use (Guina and Merrill, 2018; Robinson, 2018; Krause et al., 2019).”
BackgroundShafie, M., Rad, A. H., Mohammad‐Alizadeh‐Charandabi, S., & Mirghafourvand, M. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.06.005 · Cited by 41
Reappraising the use of benzodiazepines in chronic pain patients
Pergolizzi, J. V., & LeQuang, J. A. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1725352 · Cited by 33
“Indeed, benzodiazepines are among the most widely prescribed drugs on earth despite the fact that they are known to cause tolerance, dependence, and be associated with side effects [1,2].”
Selecting a pharmacotherapy regimen for patients with chronic insomnia
Hassinger, A. B., Bletnisky, N., Dudekula, R., & El-Solh, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1743265 · Cited by 45
“Risks include dependence, tolerance, cognitive dysfunction, withdrawal, and suicidal ideations [95].”
BackgroundPrescription Benzodiazepine Use in Privately Insured U.S. Children and Adolescents
Bushnell, G., Crystal, S., & Olfson, M. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.07.006 · Cited by 29
Society of Anesthesia and Sleep Medicine Position Paper on Patient Sleep During Hospitalization
Hillman, D. R., Carlucci, M. A., Charchaflieh, J. G., Cloward, T. V., Gali, B., Gay, P. C., Lyons, M. M., McNeill, M. M., Singh, M., Yılmaz, M., et al. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006395 · Cited by 35
Shigetsura, Y., Imai, S., Endo, H., Shimizu, Y., Ueda, K., Murai, T., Itohara, K., Nakagawa, S., Yonezawa, A., Ikemi, Y., et al. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000499 · Cited by 31
Prevalence and patterns of substance use in West Africa: A systematic review and meta-analysis
Emmanuel, G. O., Akinsolu, F. T., Abodunrin, O. R., & Ezechi, O. C. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004019 · Cited by 24
Javelot, H., Llorca, P., Drapier, D., Fakra, É., Hingray, C., Meyer, G., Dizet, S., Egron, A., Straczek, C., Roser, M. M., et al. (2020) · L Encéphale · doi:10.1016/j.encep.2020.04.006 · Cited by 28
Maciąg, M., Michalak, A., Skalicka‐Woźniak, K., Zykubek, M., Ciszewski, A., & Budzyńska, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.09.024 · Cited by 23
BDZs, Designer BDZs and Z-drugs: Pharmacology and Misuse Insights
Zaami, S., Graziano, S., Tittarelli, R., Beck, R., & Marinelli, E. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917145636 · Cited by 27
Management of Chronic Non-Cancer Pain: a Framework
Nadeau, S. E., & Lawhern, R. A. (2022) · Pain Management · doi:10.2217/pmt-2022-0017 · Cited by 27
Borgonetti, V., Les, F., López, V., & Galeotti, N. (2020) · Pharmaceuticals · doi:10.3390/ph13120472 · Cited by 21
Pisani, S., McGoohan, K., Velayudhan, L., & Bhattacharyya, S. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00882-2 · Cited by 24
“CBMs could be comparable to those reported by individuals taking anxiolytics such as benzodiazepines [59, 60] and anti-depressants [61].”
ResultWolfschlag, M., Grudet, C., & Håkansson, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.731297 · Cited by 24
“Benzodiazepines have been criticised for their adverse effects and antihistamines are used as one possible pharmacological alternative (24).”
BackgroundJain, R., Kong, A. M., Gillard, P. J., & Harrington, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02112-6 · Cited by 25
“While benzodiazepines can be helpful, there is growing concern about misuse, as this medication class can influence decision-making, increase risk of falls, and negatively affect memory [33].”
BackgroundMukty, S. A., Hasan, R., Bhuia, M. S., Saha, A. K., Rahman, U. S., Khatun, M. M., Bithi, S. A., Ansari, S. A., Ansari, I. A., & Islam, M. T. (2024) · Drug Development Research · doi:10.1002/ddr.22250 · Cited by 24
“Elderly individuals using BZDs are at higher risk of attempted and completed suicide (Guina & Merrill, 2018).”
Dependence on hypnotics: a comparative study between chronic users of benzodiazepines and Z-drugs
Curado, D. F., de Barros, V. V., Noto, A. R., & Opaleye, E. S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1651 · Cited by 24
Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids
Kleinman, R. A., & Schatzberg, A. F. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20020134 · Cited by 18
Benzodiazepine Use and Dependence in Relation to Chronic Pain Intensity and Pain Catastrophizing
Lape, E. C., Powers, J. M., Hooker, J. E., Edwards, R. R., & Ditre, J. W. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.09.019 · Cited by 22
1,4-Benzodiazepines and New Derivatives: Description, Analysis, and Organic Synthesis
Batlle, E., Lizano, E., Viñas, M., & Pujol, M. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79879 · Cited by 26
“Despite many clinicians intending to interrupt them after the 4–6 weeks (when SSRIs begin to have their therapeutic effect), 12% of patients receiving this treatment and trialed at the study previously mentioned to continue BZDs for over 6 months—sometimes in the absence of SSRIs—likely indicating the difficulty of di…”
BackgroundInfluentialThe emergence of antidepressant drugs targeting GABAA receptors: A concise review
Gonda, X., Tarazi, F. I., & Döme, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116481 · Cited by 19
Coll, S., Walsh, M. E., Fahey, T. P., & Moriarty, F. (2021) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2021.06.001 · Cited by 19
Mapping the insomnia patient journey in Europe and Canada
O'Regan, D. J., García-Borreguero, D., Gloggner, F., Wild, I., Leontiou, C., & Ferini‐Strambi, L. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1233201 · Cited by 21
“, beyond 4 weeks) (43–45), thus increasing the risk of adverse effects such as dependency (46).”
BackgroundInternet-Based Cognitive Behavioral Therapy for Insomnia in Appalachian Women: A Pilot Study
Moloney, M., Martinez, A. I., Badour, C. L., & Moga, D. C. (2019) · Behavioral Sleep Medicine · doi:10.1080/15402002.2019.1661249 · Cited by 20
“Extended sleep medication use may lead to tolerance and dependence – a noteworthy concern considering that individuals with chronic sleep disturbances are at a higher risk for drug misuse and abuse (Guina & Merrill, 2018).”
BackgroundToolabi, M., Khoramjouy, M., Aghcheli, A., Ayati, A., Moghimi, S., Firoozpour, L., Shahhosseini, S., Shojaei, R., Asadipour, A., Divsalar, K., et al. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000066 · Cited by 17
Combination therapy with neuropeptides for the treatment of anxiety disorder
Gupta, P. R., & Prabhavalkar, K. S. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102127 · Cited by 21
Zou, G., Xia, J., Han, Q., Liu, D., & Xiong, W. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011221 · Cited by 17
“However, benzodiazepines may cause sedative effects even at low doses (54), which is far from ideal for long-term treatment and children.”
BackgroundWebber, H. E., Badawi, J. C., Schmitz, J. M., Yoon, J. H., Calvillo, D. J., Becker, C. I., & Lane, S. D. (2024) · Journal of Sleep Research · doi:10.1111/jsr.14330 · Cited by 18
“We refer the reader to current reviews on the topic (de Mendonça et al., 2021; Guina & Merrill, 2018; Holbrook et al., 2000).”
Saloner, R., Grelotti, D. J., Tyree, G. A., Sundermann, E. E., Ma, Q., Letendre, S. L., Heaton, R. K., & Cherner, M. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002183 · Cited by 19
Chen, Y., Liu, C.-Y., Chang, C., Lai, Y., Wang, B., Yang, T., & Hsu, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.077 · Cited by 15
Fink, P. B., Wheeler, A. R., Smith, W. R., Brant-Zawadzki, G. M., Lieberman, J. R., McIntosh, S. E., Tilburg, C. V., Wedmore, I. S., Windsor, J. S., Hofmeyr, R., et al. (2024) · Wilderness and Environmental Medicine · doi:10.1177/10806032241248422 · Cited by 20
“207 Additionally, the combination of BZDs with other CNS depressants can potentiate their concerning adverse effects.”
BackgroundOstuzzi, G., Papola, D., Gastaldon, C., Schoretsanitis, G., Bertolini, F., Amaddeo, F., Cuomo, A., Emsley, R. A., Fagiolini, A. M., Imperadore, G., et al. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18308 · Cited by 17
Coteur, K., Henrard, G., Schoenmakers, B., Laenen, A., den Broeck, K. V., Sutter, A. D., Anthierens, S., Devroey, D., Kacenelenbogen, N., Offermans, A.-M., et al. (2022) · SLEEP · doi:10.1093/sleep/zsac278 · Cited by 22
Yoga: Balancing the excitation-inhibition equilibrium in psychiatric disorders
Mehta, U. M., & Gangadhar, B. N. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.024 · Cited by 21
A Need for Benzodiazepine Deprescribing in the COVID-19 Pandemic: A Cohort Study
Bužančić, I., Pejaković, T. I., & Hadžiabdić, M. O. (2022) · Pharmacy · doi:10.3390/pharmacy10050120 · Cited by 16
Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
Modesto‐Lowe, V., Chaplin, M., León-Barriera, R., & Jain, L. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23061 · Cited by 24
“5,23,27, According to motivation theory, people go through several stages when changing their behavior, including benzodiaze-pine use 8,25 : Precontemplation.”
BackgroundInfluentialDrug treatment strategies for insomnia in patients with post-traumatic stress disorder
Akinnusi, M. E., & Solh, A. A. E. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574745 · Cited by 16
“There is typically a rapid relief of insomnia initially, followed by a gradual loss of efficacy[35].”
BackgroundMaruta, J., Cho, C., Raphan, T., & Yakushin, S. B. (2024) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2024.1331135 · Cited by 13
Contribution of benzodiazepines in dental care of patients with special needs
Picciani, B., dos Santos, B., Silva-Júnior, G. O., Marinho, M., Papa, E., Faria, M., Bastos, L., & de Gouvea, C. (2019) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.56149 · Cited by 13
“Its action occurs through the interaction of the drug with specific receptors in the central nervous system, promoting sedation, hypnosis, anxiety control, skeletal muscle relaxation, anterograde amnesia, anticonvulsant activity, reduction of salivary flow and vomiting reflex (7,8).”
BackgroundShould gabapentinoids be prescribed long-term for anxiety and other mental health conditions?
Horowitz, M. A., Kelleher, M., & Taylor, D. M. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.106943 · Cited by 13
de Barros, V. V., Opaleye, E. S., Demarzo, M., Curado, D. F., Bowen, S. W., Hachul, H., & Noto, A. R. (2021) · International Journal of Behavioral Medicine · doi:10.1007/s12529-021-10002-4 · Cited by 16
“Also, individuals with insomnia are more likely to have anxiety and depression [5], which can be worsened by hypnotic consumption [6].”
BackgroundVukičević, T., Draganić, P., Škribulja, M., Puljak, L., & Došenović, S. (2023) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-023-02574-1 · Cited by 12
“…alcohol, sedative/hypnotic withdrawal, and catatonia, there are only 4 evidence-based psychiatric indications for benzodiazepine use (panic disorder, generalized anxiety disorder, social anxiety disorder, and insomnia) and only in short-term (less than 2–4 weeks) for treatment-resistant cases [37].”
Careful Prescribing of Benzodiazepines during COVID-19 Pandemic: A Review
Agrawal, R. (2020) · JOURNAL OF MENTAL HEALTH AND CLINICAL PSYCHOLOGY · doi:10.29245/2578-2959/2020/4.1214 · Cited by 14
Heinemann, S., Brockmöller, J., Hagmayer, Y., & Himmel, W. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02783-1 · Cited by 15
“While these drugs may help patients to sleep in the hospital environment, they also have adverse effects, such as confusion, falls, fractures, and craving [6] so they are not recommended for the treatment of transient sleep problems in most guidelines [7].”
BackgroundMarković, S. Z., Jovanović, N. I. D., Sedić, B., Vuković, M., Okjan, J. J., Dimitrijević, I., Trikos, L., Mojović, M., & Kastratović, D. A. (2019) · PubMed · Cited by 13
Postmortem Analysis of Benzodiazepines in Human Bone by Gas Chromatography–Mass Spectrometry
Mancini, R., Fernadez-Lopez, L., Romero, M. F., Pellegrini, M., Maldonado, A. L., & Rotolo, M. C. (2020) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa020 · Cited by 11
Cai, L., Tao, Q., Li, W., Zhu, X., & Cui, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.971853 · Cited by 11
Kaye, A. D., Tassin, J. P., Upshaw, W. C., Robichaux, C., Frolov, M. V., Dupaquier, M. M., Fox, J., Sterritt, J., Mathew, J. S., Shekoohi, S., et al. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00628-3 · Cited by 11
“Additionally, alprazolam may be misused in order to achieve a euphoric state by causing disinhibition of dopaminergic neurons which project to the nucleus accumbens [3].”
BackgroundBoarescu, I., & Boarescu, P.-M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11120406 · Cited by 18
“The administration of benzodiazepines can be helpful to reduce adrenergic stimulation and anxiety [134,135].”
Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial
Faay, M. D. M., van Baal, G. C. M., Arango, C., Díaz‐Caneja, C. M., Berger, G. E., Leucht, S., Bobes, J., Sáiz, P. A., García‐Portilla, M. P., van de Brug, R., et al. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.08.021 · Cited by 11
“, 2018) and the decreased inhibition benzodiazepines cause might also increase impulsivity and dangerous behaviour (Guina and Merrill, 2018).”
BackgroundHuang, K., Tai, C., Kuan, Y., Chang, Y.-C., Tsai, T., & Lee, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179410 · Cited by 13
Rijksen, D. O. C., Zuidema, S. U., & de Haas, E. C. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210041 · Cited by 18
“In addition, older persons are known to be especially sensitive to the psychomotor and cognitive side effects of BZRAs, such as drowsiness, dizziness, falls and fractures, cognitive deterioration, and delirium [9, 10].”
Paterson, A., Khundakar, M., Young, A., Ling, J., Chakraborty, S. P., Rathbone, A. P., Watson, S., Donaldson, T., & Anderson, K. N. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.41 · Cited by 12
Cardona-Acosta, A. M., Sial, O. K., Parise, L. F., Gnecco, T., Marti, G. E., & Bolaños‐Guzmán, C. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-37696-8 · Cited by 9
Impact of chronic medications in the perioperative period –anesthetic implications (Part II)
Elvir-Lazo, O. L., White, P. F., Eng, H. C., Yumul, F., Chua, R., & Yumul, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1982298 · Cited by 9
“midazolam, clonazepam, and diazepam) are primarily metabolized via hepatic cytochrome P450 (microsomal oxidation) pathway (CYP3A4) and have potentially long-acting metabolites with prolonged administration[47].”
BackgroundComplementary and Integrative Health Interventions for Insomnia in Veterans and Military Populations
Staples, J. K., Gibson, C., & Uddo, M. M. (2021) · Psychological Reports · doi:10.1177/00332941211048473 · Cited by 11
Trager, R. J., Cupler, Z. A., Delano, K. J., Perez, J. A., & Dusek, J. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058769 · Cited by 9
Pharmacogenetics of anxiety disorders
McGowan, O. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134443 · Cited by 11
Azab, I. H. E., & Elkanzi, N. A. A. (2020) · Molecules · doi:10.3390/molecules25092051 · Cited by 10
Occupational Injuries and Use of Benzodiazepines: A Systematic Review and Metanalysis
Garbarino, S., Lanteri, P., Bragazzi, N. L., Gualerzi, G., & Riccò, M. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.629719 · Cited by 13
“, driving and operating machinery), with eventually increased risk for occupational injuries (Guina and Merrill, 2018; Kowalski-McGraw et al., 2018), the role of BDZ in occupational injuries remains controversial.”
BackgroundDu, L. P., Xu, S., Wu, H., Zhao, T., Wang, X., & Wang, M. (2021) · Molecules · doi:10.3390/molecules26175209 · Cited by 9
Bharathi, G. S. S., Lalitha, V., Sethumathi, P. P., Sivakumar, T., Selvi, P. P., Kavitha, M., & Kumar, R. (2021) · Annals of Phytomedicine An International Journal · doi:10.21276/ap.2021.10.2.4 · Cited by 12
Dhangar, R. R., Kale, P. P., Kadu, P. K., & Prabhavalkar, K. S. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00207-3 · Cited by 9
Agrawal, R., Verma, S., & Halappanavar, M. (2020) · Community Mental Health Journal · doi:10.1007/s10597-020-00686-5 · Cited by 9
Icick, R., Melle, I. S., Étain, B., Høegh, M. C., Gard, S., Aminoff, S. R., Leboyer, M., Andreassen, O. A., Belzeaux-R, R., Henry, C., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.813256 · Cited by 10
Mousavi, Z., Khazaie, H., Janatolmakan, M., Rezaeian, S., & Khatony, A. (2023) · BMC Medical Education · doi:10.1186/s12909-023-04825-w · Cited by 14
“Benzodiazepines are commonly prescribed drugs for treating test anxiety; however, they entail various side effects, including addiction, memory impairment/amnesia, and reduced concentration [17, 18].”
BackgroundBest practices in benzodiazepine prescribing and management in primary care
Champion, C., & Kameg, B. (2021) · The Nurse Practitioner · doi:10.1097/01.npr.0000733684.24949.19 · Cited by 9
Roh, E., Cota, E., Lee, J. P., Madievsky, R., & Eskildsen, M. A. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.05.007 · Cited by 11
Valadez-Renteria, E., UC, J. O., Navarro-Garcia, N., & Rodríguez‐González, V. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-26669-z · Cited by 8
Metadata
- Authors
- Guina, J., & Merrill, B.
- Affiliations
- Wright State University (US)
- Corresponding author
- Guina, Jeffrey
- ORCID
- Guina, Jeffrey
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2018-01-30
- Volume
- 7
- Issue
- 2
- Pages
- 17
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC5852433
- OpenAlex
- W2793017265
- Semantic Scholar
- 81e4137cd04cbc40756500350418397c8843db63
- Cited by
- 253
- References
- 99
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 34 · 2023: 42 · 2022: 32 · 2021: 42 · 2020: 34 · 2019: 25 · 2018: 6
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Journal of Bioresource Management (submittedVersion, cc-by)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepines, sedative-hypnotic drugs, anxiety, insomnia, adverse effects, drug-drug interactions, long-term benzodiazepine use, psychotherapy, sleep hygiene, serotonergic agents, functional recovery, biopsychosocial model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.